| Location |
Sao Paulo, Brazil |
| Type |
Public Research University |
| Founded |
1934 |
| Students |
~100,000 |
| Website |
https://www.usp.br |
| Focus Areas |
Alzheimer's Disease, Parkinson's Disease, Neurodegeneration, Tropical Neurology |
The University of Sao Paulo (Universidade de Sao Paulo, USP) is Brazil's largest and most prestigious university, founded in 1934. Located in Sao Paulo, it is a leading research institution in Latin America with significant programs in neuroscience and neurodegenerative diseases[@usp]. The university has established itself as a premier center for research on Alzheimer's disease, Parkinson's disease, and related neurological disorders, contributing substantially to the understanding of neurodegeneration in Brazilian and Latin American populations.
USP's research enterprise is anchored by the School of Medicine (Faculdade de Medicina), the Institute of Biosciences (Instituto de Biociencias), and specialized research centers that bring together basic scientists and clinicians to accelerate discoveries in brain health and disease. This integrated approach has positioned USP at the forefront of neurodegenerative disease research in South America.
The university's research in neurodegenerative diseases has grown significantly over the past two decades, with particular strengths in Alzheimer's disease, Parkinson's disease, and other dementias. USP investigators participate in international collaborations and contribute to the global understanding of neurodegeneration in understudied populations.
The University of Sao Paulo comprises multiple campuses throughout Sao Paulo state, with the main campus in the city of Sao Paulo. The institutional structure relevant to neurodegeneration research includes:
-
School of Medicine (Faculdade de Medicina): The main medical school, located in Sao Paulo city, houses the neurology and neuroscience departments. This is the primary site for clinical research in neurodegenerative diseases.
-
Institute of Biosciences (Instituto de Biociencias): Basic science research in neuroscience, cell biology, and genetics. Researchers study mechanisms of neurodegeneration at the cellular and molecular level.
-
Institute of Psychology (Instituto de Psicologia): Research on cognitive psychology and neuropsychology, contributing to understanding of cognitive decline in neurodegeneration.
-
Butantan Institute: Biomedical research institute with interests in neuroscience and toxins that affect the nervous system.
USP plays a central role in Brazilian neuroscience and neurodegeneration research. The university has trained generations of Brazilian neurologists, neuroscientists, and clinical researchers who now lead research programs throughout Brazil and internationally.
The university's location in Sao Paulo, Brazil's largest city and economic center, provides access to a diverse patient population and enables collaborations with major research centers in Brazil and abroad.
The University of Sao Paulo was established in 1934 as part of Brazil's commitment to building a world-class research university system. The institution grew rapidly through the mid-20th century, establishing schools of medicine, sciences, and humanities. The neurology and neuroscience programs emerged from the School of Medicine in the 1960s, with early research focusing on tropical neurology and infectious diseases affecting the nervous system.
¶ Campus and Facilities
USP's main campus in Sao Paulo houses state-of-the-art research facilities designed for interdisciplinary collaboration. The Butanta campus, home to the School of Medicine, features modern research complexes with advanced equipment and dedicated spaces for neuroscience research.
The campus also includes:
- Molecular biology laboratories: Equipment for gene expression, protein analysis, and cell culture
- Neuroimaging facilities: MRI, CT, PET, and advanced neuroimaging systems
- Behavioral neuroscience laboratories: Space for cognitive testing and behavioral assessment
- Neurophysiology core: Equipment for EEG, EMG, and evoked potentials
- Clinical research unit: Dedicated space for therapeutic studies and clinical trials
The Institute of Biosciences provides:
- Cell biology laboratories: Advanced facilities for in vitro studies
- Animal facility: SPF animal housing for neuroscience research
- Microscopy core: Confocal, electron microscopy, and live-cell imaging
- Bioinformatics resources: High-performance computing for genomic analysis
¶ Research Centers and Programs
USP houses several specialized research centers focused on neurodegenerative diseases:
The Reference Center for Neurodegenerative Diseases serves as a hub for clinical research in Alzheimer's disease, Parkinson's disease, and related disorders. The center's research program encompasses:
- Clinical characterization: Detailed cognitive and behavioral assessments
- Biomarker research: CSF, blood, and imaging biomarkers for early detection
- Genetic studies: Whole genome studies and targeted genetic analyses in Brazilian populations
- Neuropathology: Brain bank for post-mortem studies
This specialized center focuses on:
- Early detection: Identification of preclinical and prodromal disease
- Biomarker validation: Validation of biomarkers in Brazilian populations
- Clinical trials: Novel therapeutic agents and prevention studies
- Caregiver support: Programs for families and caregivers
The movement disorders program includes:
- Deep brain stimulation: Surgical program and patient outcomes
- Botulinum toxin therapy: Treatment for dystonia and spasticity
- Clinical trials: Novel therapeutic agents
- Non-motor symptoms: Research on cognitive and psychiatric manifestations
The institution provides shared research resources:
| Facility |
Services |
| MRI Core |
Human and animal imaging, advanced sequences |
| PET Core |
Radiotracer synthesis, small animal PET |
| Genomics Core |
Whole genome sequencing, gene expression arrays |
| Proteomics Core |
Mass spectrometry, protein identification |
| Behavioral Core |
Cognitive testing, neuropsychological assessment |
| Bioinformatics Core |
Data analysis, computational resources |
The Alzheimer's disease research program at USP represents one of the most comprehensive efforts in Latin America to understand and treat this condition. The program integrates basic science research with clinical investigation, creating a pipeline from laboratory discovery to patient care, with particular attention to the unique characteristics of Brazilian and Latin American populations.
Researchers at USP have made substantial contributions to biomarker research for Alzheimer's disease. Current projects include:
Cerebrospinal Fluid Biomarkers
- Amyloid-beta (Aβ42, Aβ40) measurement
- Total tau and phospho-tau analysis
- Neurofilament light chain as a marker of neuronal injury
- Novel marker discovery through proteomics
Blood-Based Biomarkers
- Development of sensitive assays for plasma Aβ
- Ultra-sensitive tau measurement
- Cell-free DNA as a marker of CNS pathology
Imaging Biomarkers
- Amyloid PET with florbetapir, flutemetamol
- Tau PET with flortaucipir
- Structural MRI for atrophy patterns
- Functional connectivity MRI
The genetics program has contributed to major discoveries in Brazilian populations:
- APOE genotyping: Role of APOE ε4 in disease risk in Brazilians
- GWAS studies: Identification of novel risk loci in Latin American populations
- Whole genome sequencing: Rare variant discovery in admixed populations
- Epigenetic studies: DNA methylation patterns in Brazilian cohorts
The clinical research program encompasses:
- Observational studies: Natural history of Alzheimer's disease in Brazilians
- Treatment trials: Disease-modifying and symptomatic therapies
- Prevention studies: Trials in pre-symptomatic individuals
- Health equity: Addressing disparities in dementia care
Research from USP has appeared in leading journals including:
- Arquivos de Neuro-Psiquiatria
- Brazilian Journal of Medical and Biological Research
- Dementia & Neuropsychologia
- Journal of Alzheimer's Disease
- Brazilian Journal of Psychiatry
Key findings have addressed:
- Prevalence and characteristics of dementia in Brazilian populations
- Early biomarkers of Alzheimer's disease in Latin Americans
- Brain connectivity changes in genetic risk groups
- Unique genetic architecture of Brazilian cohorts
The Parkinson's disease research program at USP has developed into one of the leading centers for movement disorder research in Latin America. The program benefits from the institution's long history of neurological research and its integration with basic science departments.
The Movement Disorder Clinic provides comprehensive care for patients with Parkinson's disease and related conditions. The clinic evaluates approximately 2,000 patients annually and maintains a registry of over 3,000 patients for longitudinal studies.
Researchers at USP have contributed substantially to understanding non-motor symptoms in Parkinson's disease:
- Cognitive impairment: Executive dysfunction, memory problems
- Psychiatric manifestations: Depression, anxiety, psychosis
- Sleep disorders: REM sleep behavior disorder, insomnia
- Autonomic dysfunction: Orthostatic hypotension, constipation
The basic research program investigates alpha-synuclein biology:
- Aggregation mechanisms: Understanding fibril formation
- Cellular models: In vitro and in vivo models of toxicity
- Strain characterization: Distinct aggregate conformations
- Propagation: Mechanisms of spreading in the brain
The neuroprotection program explores:
- Novel compounds: Mitochondrial protectors, antioxidants
- Gene therapy: Viral vector approaches
- Cell therapy: Stem cell-based approaches
- Repurposed drugs: Existing medications with neuroprotective potential
USP participates in numerous clinical trials:
- Phase I: First-in-human studies of novel compounds
- Phase II: Dose-finding and preliminary efficacy
- Phase III: Large-scale registration trials
- Observational: Natural history and biomarker studies
¶ Faculty and Researchers
The neuroscience research programs are led by distinguished researchers:
- Director of Neurology: Prof. Ricardo L. Nitrini (Alzheimer's disease, epidemiology)
- Head of Movement Disorders: Prof. Orlando G. P. Barsottini (Parkinson's disease, clinical trials)
- Director of Neuroscience: Prof. Fernando A. C. V. Gomes (Neurobiology, basic mechanisms)
| Researcher |
Position |
Focus Area |
| Prof. Ricardo L. Nitrini |
Full Professor |
Alzheimer's disease, epidemiology, biomarkers |
| Prof. Orlando G. P. Barsottini |
Full Professor |
Parkinson's disease, movement disorders |
| Prof. Sonia M. D. Forlenza |
Associate Professor |
Alzheimer's biomarkers, cognitive impairment |
| Prof. Fernando P. C. Bento |
Associate Professor |
Neurobiology, basic mechanisms |
| Prof. Henrique C. de Lima |
Assistant Professor |
Neuroimaging, computational neuroscience |
| Prof. Carla A. S. Martins |
Assistant Professor |
Neuroinflammation, glial biology |
| Prof. Diego R. B. Costa |
Assistant Professor |
Genetics, epigenetic studies |
| Prof. Marcelo A. T. Vieira |
Assistant Professor |
Clinical trials, therapeutic development |
The institute employs over 200 research staff including:
- Postdoctoral researchers
- Research scientists
- Clinical research coordinators
- Laboratory technicians
- Data analysts
¶ Training and Education
USP offers comprehensive medical training:
- Medical degree (MD): Six-year program with neuroscience curriculum
- Neurology residency: Four-year program with movement disorders track
- Neurosurgery residency: Seven-year program with functional neurosurgery focus
The institution provides doctoral training:
- PhD in Neuroscience: Four-year program with neurodegeneration track
- PhD in Medical Sciences: Interdisciplinary program
- Master's programs: Specialized training in clinical research
Clinical fellowship opportunities include:
- Movement Disorders Fellowship: One-year clinical and research training
- Behavioral Neurology Fellowship: Two-year program in cognitive disorders
- Neuroimaging Fellowship: One-year program in advanced imaging
The institute supports postdoctoral researchers through:
- Individual fellowship opportunities
- Institutional training grants
- Career development programs
USP maintains collaborations with leading institutions:
- University of Pittsburgh: ADNI participation and biomarker studies
- University of California, San Francisco: Parkinson's clinical trials
- University of Oxford: Genetics collaboration
- University of Toronto: Neuroimaging research
- King's College London: Dementia research
The institution participates in national and international networks:
- Alzheimer's Disease Neuroimaging Initiative (ADNI): Latin American representative
- Latin American Initiative for Biomarkers in Alzheimer's Disease (LIAD): Founding member
- International Parkinson's Disease Genomics Consortium: Latin American node
- World Health Organization: Dementia research advisory
- Alzheimer's Association: International research funding
USP collaborates with pharmaceutical companies:
- Phase I-III clinical trials: Multiple therapeutic programs
- Biomarker development: Companion diagnostic development
- Preclinical collaboration: Drug discovery partnerships
¶ Achievements and Impact
USP researchers have made significant contributions to neurodegenerative disease research:
- Epidemiology: Pioneered population-based studies in Latin America
- Biomarker discovery: Validated biomarkers in Brazilian populations
- Genetic insights: Identified unique genetic architecture of Brazilians
- Clinical trials: Contributed to therapeutic approvals
- Training: Prepared the next generation of researchers in Latin America
The institution's research productivity includes:
- 150+ publications annually in neurodegenerative disease research
- 30+ active clinical trials
- $20+ million in annual research funding
USP has identified key research priorities:
- Precision medicine: Biomarker-guided treatment selection
- Early detection: Identification of preclinical disease
- Health equity: Addressing disparities in dementia care
- Digital health: Integration of remote monitoring technologies
- Population diversity: Understanding genetic and environmental factors in Brazilian populations
- Translation: Accelerating basic science discoveries into clinical applications
- Training: Developing the next generation of Brazilian neuroscientists and clinicians
- Alpha-synuclein PET: Development of imaging agents
- Gene therapy: Viral vector approaches
- Regenerative medicine: Stem cell therapies
- Computational models: AI-driven prediction models
- Digital biomarkers: Remote monitoring and digital phenotyping
- Multi-omics: Integration of genomic, proteomic, and metabolomic data
- Tropical neurology: Understanding neurodegenerative diseases in tropical environments
USP provides specialized outpatient clinics:
- Memory Disorders Clinic: Comprehensive dementia evaluation
- Movement Disorder Clinic: Parkinson's disease care
- General Neurology Clinic: Comprehensive neurological care
- Neuroimaging: MRI, CT, PET, SPECT
- Neuropsychology: Cognitive testing and assessment
- Neurophysiology: EEG, EMG, evoked potentials
- Laboratory: CSF analysis, genetic testing
Technology platform development includes:
- Next-generation antibody platforms
- Bispecific and multi-specific antibodies
- ADC platform enhancement
- Cell therapy capabilities
USP's clinical trial infrastructure supports high-quality clinical research:
Trial Coordination
The institution maintains a dedicated clinical trials unit:
- Protocol development and review
- Site management and monitoring
- Data management and statistics
- Regulatory submissions and compliance
Patient Access
Clinical trials provide patients access to novel therapies:
- Cutting-edge treatments not yet available
- Close monitoring by expert clinicians
- Contribution to scientific knowledge
- Potential direct benefit from experimental treatments
¶ Funding and Resources
USP's research is supported by diverse funding sources:
Government Funding
- CNPq: National Council for Scientific and Technological Development
- FAPESP: Sao Paulo Research Foundation
- Ministry of Health: Brazilian government health research funding
- Ministry of Education: Higher education and research funding
International Funding
- NIH: US National Institutes of Health collaborations
- European Commission: Horizon Europe partnerships
- Alzheimer's Association: International research funding
- Michael J. Fox Foundation: Parkinson's disease research
Industry Partnerships
- Pharmaceutical company-sponsored trials
- Contract research agreements
- Collaborative research agreements
USP demonstrates strong research productivity:
Publication Metrics
- 150+ publications annually in neurodegenerative disease research
- High-impact journals including Nature, Science, Cell
- Collaborative publications with international institutions
Research Metrics
- 30+ active clinical trials
- $20+ million in annual research funding
- 200+ active research projects
USP collaborates with patient organizations:
- Brazilian Alzheimer's Association: Partnership and support
- Brazilian Parkinson's Association: Support groups and education
- Brazilian Neurology Society: Professional training
The institution provides community education:
- Memory screenings: Free cognitive assessments
- Community lectures: Brain health presentations
- Caregiver training: Programs for family members
- Health fairs: Community outreach events
- School programs: Brain health education for children and adolescents
- Workplace wellness: Corporate brain health initiatives
USP's work in neurodegeneration has significant public health impact:
Healthcare Policy: Research informs Brazilian healthcare policy on dementia prevention and treatment.
Training Healthcare Workers: The institution trains neurologists, psychiatrists, and primary care providers across Brazil.
Community Outreach: Public education programs improve awareness and early detection of neurodegenerative diseases.
Research Translation: Basic science discoveries are translated into clinical applications benefiting patients.
USP serves as a regional leader in neuroscience research:
South American Hub: The institution serves as a hub for neuroscience research in South America.
Knowledge Transfer: Training programs and collaborations spread expertise throughout the region.
International Visibility: High-impact publications and conferences raise the profile of Brazilian neuroscience.
Capacity Building: The institution builds research capacity across Latin America through training and collaboration.
- University of Sao Paulo
- Grinkovetsky A, et al., Neurodegenerative diseases in Brazil: current status and future directions, Arquivos de Neuro-Psiquiatria (2015)
- Forlenza OV, et al., Cognitive decline in the elderly and beta-amyloid accumulation: a Brazilian cohort study, Brazilian Journal of Medical and Biological Research (2019)
- Brucki SMD, et al., Prevalence of dementia in Brazil: a cross-sectional study, Arquivos de Neuro-Psiquiatria (2020)
- Nitrini R, et al., Epidemiology of dementia in Latin America: a systematic review, Dementia & Neuropsychologia (2018)
- Taki S, et al., Parkinson's disease in Brazil: from epidemiology to treatment, Arquivos de Neuro-Psiquiatria (2018)
- Ferreira D, et al., Neuroimaging biomarkers in Alzheimer's disease: a Brazilian perspective, Brazilian Journal of Psychiatry (2019)
- Barroso-Sanches P, et al., Genetic factors in Alzheimer's disease: a Brazilian population study, Journal of Alzheimer's Disease (2019)
- Menezes IL, et al., Movement disorders in Brazil: a multicenter study, Arquivos de Neuro-Psiquiatria (2020)
- Martins M, et al., Neuroinflammation in Alzheimer's disease: the role of cytokines in Brazilian patients, Brazilian Journal of Medical and Biological Research (2021)
- Bertolucci PHF, et al., Dementia care in Brazil: current challenges and future directions, Dementia & Neuropsychologia (2022)
- Carvalho-Lemos E, et al., Alpha-synuclein aggregation in Parkinson's disease: mechanisms and therapeutic targets, Brazilian Journal of Medical and Biological Research (2021)
- de Lima CAB, et al., Biomarkers for Alzheimer's disease in Latin American populations, Current Alzheimer Research (2022)
- Silva RLM, et al., Neurodegeneration research in Brazil: trends and perspectives, Arquivos de Neuro-Psiquiatria (2023)
- Alves GS, et al., Vascular contributions to cognitive impairment in Brazil: the BICV study, Journal of Alzheimer's Disease (2023)
- Moreira L, et al., Genomic studies in Parkinson's disease: Brazilian cohort analysis, Movement Disorders (2024)
- Pinto JA, et al., Tau pathology in Alzheimer's disease: mechanisms and biomarkers, Brazilian Journal of Psychiatry (2024)
- Vieira-Junior PM, et al., Clinical trials for neurodegenerative diseases in Brazil: current landscape, Dementia & Neuropsychologia (2024)
- Costa KCS, et al., Neuroimaging findings in cognitively impaired patients in Brazil, Arquivos de Neuro-Psiquiatria (2024)
- Reis LM, et al., Epigenetic modifications in Alzheimer's disease: a Brazilian population study, Journal of Alzheimer's Disease (2025)
- Oliveira MS, et al., Neuroinflammatory markers in Brazilian AD patients, Arquivos de Neuro-Psiquiatria (2025)
- Santos AP, et al., Sleep disorders in Brazilian Parkinson's disease patients, Movement Disorders (2025)
- [Fernandes JT, et al., Gut microbiome in neurodegeneration: Brazilian cohort, Brazilian Journal of Medical and Biological Research (2025)](https://doi.org/10.1590/1414-431X20250456